N-diphenylmethyl-propylamine | 51411-31-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-diphenylmethyl-propylamine
• 英文别名: benzhydryl-propyl-amine；Benzhydryl-propyl-amin；N-diphenylmethyl-N-propylamine；N-benzhydrylpropan-1-amine
• CAS: 51411-31-5
• 化学式: C₁₆H₁₉N
• mdl: MFCD11127839
• 分子量: 225.334
• InChiKey: NRPLRSMUIHGFPI-UHFFFAOYSA-N

物化性质

• 沸点：
  144-146 °C(Press: 3 Torr)
• 密度：
  0.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-diphenylmethyl-propylamine 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 苯 为溶剂， 反应 5.0h， 生成 Benzophenon-propylimid
  参考文献：
  名称：

  二苯甲胺：合成伯胺的有效胺化剂

  摘要：

  醛、酮、烷基甲苯对磺酸盐和卤化物被转化为相应的伯胺，二苯甲基胺作为一种有价值的氨合成子，收率中等至极好。

  DOI：

  10.3184/174751918x15232662638058
• 作为产物：
  描述：

  Benzophenon-propylimid 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 N-diphenylmethyl-propylamine
  参考文献：
  名称：

  Sharma, Indra; Ray, Suprabhat, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1985, vol. 24, p. 59 - 61

  摘要：

  DOI：

文献信息

• Can One Predict Changes from S_N1 to S_N2 Mechanisms?
  作者：Thanh Binh Phan、Christoph Nolte、Shinjiro Kobayashi、Armin R. Ofial、Herbert Mayr

  DOI：10.1021/ja903207b

  日期：2009.8.19

  lifetimes of benzhydrylium ions in the presence of amines and DMSO. The change from S(N)1 to S(N)2 mechanism occurred close to the point where the calculated rate constant for the collapse of the benzhydrylium ions with the amines just reaches the vibrational limit; that is, the concerted S(N)2 mechanism was only followed when it was enforced by the lifetime of the intermediate. The nucleophile-specific

  取代的二苯甲基溴化物 Ar(2)CHBr 与伯胺和仲胺在 DMSO 中的反应产生二苯甲基胺 Ar(2)CHNRR'、二苯甲酮 Ar(2)C=O 和二苯甲醇 Ar(2)CHOH。20 摄氏度的动力学研究揭示了速率定律 -d[Ar(2)CHBr]/dt = (k(1) + k(2)[HNRR'])[Ar(2)CHBr]，其中胺独立项k(1) 导致形成 Ar(2)C=O 和 Ar(2)CHOH，胺依赖项 k(2)[HNRR'] 负责形成 Ar(2)CHNRR'。获得了伴随 S(N)1 和 S(N)2 过程的明确证据。虽然 S(N)1 反应的速率常数与哈米特 sigma(+) 常数 (rho = -3.22) 相关，但 S(N)2 反应的二级速率常数 k(2) 与取代基的电子释放能力，表明 S(N)2 反应的过渡态不与 S(N)1 反应的过渡态合并。相关方程 log k(20°C) = s(E +
• [EN] MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR DE LA PROSTACYCLINE (PGI2) UTILES POUR LE TRAITEMENT DE TROUBLES LIÉS À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2009117095A1

  公开（公告）日：2009-09-24

  The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  本发明涉及式（XIIIa）的酰胺衍生物及其药物组合物，其调节PGI2受体的活性。本发明的化合物和药物组合物适用于治疗以下疾病的方法：肺动脉高压（PAH）；特发性PAH；家族性PAH；与胶原血管疾病、先天性心脏病、门脉高压、HIV感染、药物或毒素摄入、遗传性出血性毛细血管扩张症、脾切除术、肺静脉闭塞性疾病（PVOD）或肺毛细血管血管瘤病（PCH）相关的PAH；具有明显静脉或毛细血管受累的PAH；血小板聚集；冠状动脉疾病；心肌梗死；短暂性缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在介入治疗或冠状动脉旁路手术个体中或患有心房颤动的个体中；动脉粥样硬化；动脉血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或眼内压异常的其他眼部疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥反应；多发性硬化；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Reactivities of diarylmethyl and triarylmethyl cations with primary amines in aqueous acetonitrile solutions. The importance of amine hydration
  作者：Robert A. McClelland、V. M. Kanagasabapathy、Narinder S. Banait、Steen Steenken

  DOI：10.1021/ja00031a041

  日期：1992.2

  By use of the technique of laser flash photolysis, rate constants k(RNH 2 ) have been directly measured for the reactions of primary amines RCH 2 NH 2 (R=CH 3 CH 2 , CH 3 OCH 2 , NCCH 2 , CF 3 ) with diarylmethyl cations (D + ) in acetonitrile/water solutions

  利用激光闪光光解技术，直接测量了伯胺RCH 2 NH 2 (R=CH 3 CH 2 , CH 3 OCH 2 , NCCH 2 , CF 3 )反应的速率常数k(RNH 2 )乙腈/水溶液中的二芳基甲基阳离子 (D + )
• [EN] AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS<br/>[FR] THIADIAZOLES, PYRIMIDINES, TRIAZINES OU TRIAZOLES AMINO-SUBSTITUES UTILES COMME ANTAGONISTES DU RECEPTEUR DU FACTEUR DE LIBERATION DE CORTICOTROPINE
  申请人：NEUROCRINE BIOSCIENCES, INC.

  公开号：WO1996039400A1

  公开（公告）日：1996-12-12

  (EN) Compounds having formulae (I) to (VI) wherein X is a substituted (hetero)aryl group and R1-R6 are various possible substituents, are corticotropin-releasing factor (CRF) receptor antagonists.(FR) L'invention concerne des composés de formules (I) à (VI) où X est un groupe (hétéro)aryle substitué et R1-R6 sont des substituants éventuels divers. Ces composés sont des antagonistes du récepteur du facteur de libération de corticotropine.

  化合物的化学式为(I)到(VI)，其中X是取代的(杂)芳基团，R1-R6是不同的可能的取代基，是促肾上腺皮质激素释放因子（CRF）受体拮抗剂。
• MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Tran Thuy-Anh

  公开号：US20110053958A1

  公开（公告）日：2011-03-03

  The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  本发明涉及式（XIIIa）的酰胺衍生物及其药物组合物，其调节PGI2受体的活性。本发明的化合物和药物组合物针对以下治疗方法有用：肺动脉高压（PAH）；特发性PAH；家族性PAH；与胶原血管病、先天性心脏病、门静脉高压、HIV感染、药物或毒素摄入、遗传性出血性毛细血管扩张症、脾切除、肺静脉闭塞病（PVOD）或肺毛细血管瘤病（PCH）相关的PAH；有显著静脉或毛细血管参与的PAH；血小板聚集；冠状动脉疾病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在冠状动脉成形术或冠状动脉搭桥手术个体中或在患有心房颤动的个体中；动脉粥样硬化；动脉粥样硬化性血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病性周围神经病、糖尿病性肾病或糖尿病性视网膜病变；青光眼或其他眼部异常内压疾病；高血压；炎症；银屑病；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。